Melatonin Inhibits Glioma Cell Growth Through Intracellular Signaling

Melatonin Inhibits Glioma Cell Growth Through Intracellular Signaling

Preclinical research by Martín and colleagues examined how melatonin affects the growth of glioma cells, a model of aggressive brain cancer. Using cultured glioma cell lines and animal models, the investigators explored whether melatonin could suppress tumor proliferation and influence key signaling pathways involved in cancer cell survival.
In laboratory experiments, higher concentrations of melatonin significantly reduced glioma cell proliferation by inhibiting progression through the cell cycle. In animal models, daily melatonin administration resulted in a substantial reduction in tumor growth compared with untreated controls, suggesting meaningful biological activity under experimental conditions.
Mechanistically, melatonin’s anti-proliferative effects were associated with decreased activation of survival pathways such as Akt and NF-κB, along with modulation of oxidative stress within tumor cells. These changes appeared to shift cancer cells toward reduced growth and increased susceptibility to apoptosis. Notably, some of these effects were independent of classical melatonin receptor signaling, indicating additional intracellular mechanisms.
Although this study was conducted in vitro and in animal models and cannot be directly translated to patient care, it provides important mechanistic insight into how melatonin may influence glioma biology. These findings support further clinical investigation into melatonin as a potential adjunct in brain cancer treatment strategies.

Reference:

Martín V, Herrera F, Carrera-Gonzalez P, García-Santos G, Antolín I, Rodriguez-Blanco J, Rodriguez C. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res. 2006;66(2):1081–1088. doi:10.1158/0008-5472.CAN-05-2354. PMID: 16424044.